Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calendula + Echinacea (brand name Calcea) is a topical herbal and anthroposophic ointment developed by WALA Heilmittel GmbH. It contains a combination of *Calendula officinalis* (marigold) flower extract and *Echinacea purpurea/pallida* (coneflower) extract. The product is designed to treat skin barrier damage, irritant contact dermatitis, and promote wound healing. Calendula is traditionally used for its anti-inflammatory and wound-healing properties, while Echinacea provides immune-modulating and anti-inflammatory effects. The ointment has been evaluated in Phase 4 clinical trials assessing its efficacy in reducing transepidermal water loss (TEWL) and skin inflammation in models of sodium lauryl sulphate-induced irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calendula + echinacea.